ESTIMATION OF THE BUDGET SAVING POTENTIAL DUE TO THE INTRODUCTION OF BENEPALI®, AN ETANERCEPT BIOSIMILAR, FOR THE TREATMENT OF ALL LICENSED ADULT ETANERCEPT INDICATIONS IN SPAIN

被引：0

作者：

Psachoulia, E. ^{[1
]}

Casahorran, V ^{[2
]}

机构：

[1] Biogen Int GmbH, Zug, Switzerland

[2] Biogen Spain SL, Madrid, Spain

来源：

VALUE IN HEALTH | 2016年 / 19卷 / 07期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PMS21

引用

页码：A533 / A534

页数：2

共 14 条

[1] ASSESSING THE COST SAVING POTENTIAL OF INTRODUCING BENEPALI®, AN ETANERCEPT BIOSIMILAR, FOR THE TREATMENT OF ALL LICENSED ADULT ETANERCEPT INDICATIONS IN FRANCE, ITALY AND SWEDEN
Psachoulia, E.
Bresson, A.
Holmqvist, K.
Negrini, C.
[J]. VALUE IN HEALTH, 2016, 19 (07) : A533 - A533
[2] EVALUATION OF THE COST SAVING POTENTIAL OF INTRODUCING BENEPALI®, AN ETANERCEPT BIOSIMILAR, FOR THE TREATMENT OF ALL LICENSED ADULT ETANERCEPT INDICATIONS IN THREE REGIONS IN ITALY
Psachoulia, E.
Negrini, C.
[J]. VALUE IN HEALTH, 2016, 19 (07) : A534 - A534
[3] ESTIMATION OF THE BUDGET SAVING POTENTIAL DUE TO THE INTRODUCTION OF AN ETANERCEPT BIOSIMILAR (SB4) FOR THE TREATMENT OF APPROVED ADULT ETANERCEPT INDICATIONS IN BELGIUM
Psachoulia, E.
Bresson, A.
[J]. VALUE IN HEALTH, 2017, 20 (09) : A529 - A529
[4] ASSESSING THE POTENTIAL COST SAVING POTENTIAL OF IMPLEMENTING BENEPALI®, AN ETANERCEPT BIOSIMILAR, USING DISCOUNT AGREEMENTS FOR THE TREATMENT OF ALL LICENSED ETANERCEPT INDICATIONS FOR ADULTS IN SWEDEN
Psachoulia, E.
Holmqvist, K.
[J]. VALUE IN HEALTH, 2016, 19 (07) : A533 - A533
[5] ESTIMATION OF THE ADDITIONAL BUDGET SAVING POTENTIAL DUE TO THE RAPID ADOPTION OF AN ETANERCEPT BIOSIMILAR (SB4) FOR THE TREATMENT OF APPROVED ADULT ETANERCEPT INDICATIONS IN SPAIN
Psachoulia, E.
Chouman, S.
[J]. VALUE IN HEALTH, 2017, 20 (09) : A529 - A530
[6] BUDGET IMPACT ANALYSIS OF AN ETANERCEPT BIOSIMILAR FOR THE TREATMENT OF ALL LICENSED ETANERCEPT INDICATIONS FOR ADULTS IN EUROPE
Ruff, L.
Rezk, M. F.
Uhlig, T.
Gommers, J. W.
[J]. VALUE IN HEALTH, 2015, 18 (07) : A639 - A639
[7] EVALUATION OF THE COST SAVING POTENTIAL OF INTRODUCING AN ADALIMUMAB BIOSIMILAR FOR THE TREATMENT OF ALL LICENSED ADULT ADALIMUMAB INDICATIONS IN SPAIN
Barbado, G.
Waker, M.
Levysohn, A.
Bodin, M.
Keady, S.
[J]. VALUE IN HEALTH, 2019, 22 : S50 - S50
[8] EVALUATION OF THE COST SAVING POTENTIAL OF INTRODUCING AN ETANERCEPT BIOSIMILAR (SB4) FOR THE TREATMENT OF APPROVED ETANERCEPT INDICATIONS IN THE REPUBLIC OF IRELAND
Psachoulia, E.
Keady, S.
[J]. VALUE IN HEALTH, 2017, 20 (09) : A529 - A529
[9] EVALUATION OF THE COST SAVING POTENTIAL OF INTRODUCING AN ADALIMUMAB BIOSIMILAR FOR THE TREATMENT OF ALL LICENSED ADULT ADALIMUMAB INDICATIONS IN BELGIUM
Waker, M.
Levysohn, A.
Bodin, M.
Keady, S.
[J]. VALUE IN HEALTH, 2019, 22 : S47 - S48
[10] EVALUATION OF THE COST SAVING POTENTIAL OF INTRODUCING AN ADALIMUMAB BIOSIMILAR FOR THE TREATMENT OF ALL LICENSED ADULT ADALIMUMAB INDICATIONS IN THE UK
Aubrey, P.
Waker, M.
Levysohn, A.
Bodin, M.
Keady, S.
[J]. VALUE IN HEALTH, 2019, 22 : S50 - S50

← 1 2 →